Citi upgrades Amylin Pharmaceuticals Inc (Nasdaq: AMLN) from Sell to Hold. Price target lowered from $21 to $17.

This article: 100 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE